We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
+25.71%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$336M
AUM Growth
-$103M
(-24%)
Cap. Flow
-$131M
Cap. Flow
% of AUM
-39%
Top 10 Holdings %
Top 10 Hldgs %
58.57%
Holding
65
New
22
Increased
6
Reduced
11
Closed
14
Avg Time Held Equity + Options
2.8
quarters
Top 10 Avg Time Held Equity + Options
2.3
quarters
Top 20 Avg Time Held Equity + Options
1.8
quarters
Avg Time Held Equity only
2.9
quarters
Top 10 Avg Time Held Equity only
2.3
quarters
Top 20 Avg Time Held Equity only
1.8
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Labcorp
LH
|
+$13.4M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$12M |
| 3 |
Medtronic
MDT
|
+$8.96M |
| 4 |
Tyra Biosciences
TYRA
|
+$8.79M |
| 5 |
Organon & Co
OGN
|
+$8.22M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$85.3M |
| 2 |
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
|
+$50.2M |
| 3 |
Immunogen Inc
IMGN
|
+$19.1M |
| 4 |
United Therapeutics
UTHR
|
+$17.6M |
| 5 |
Cigna
CI
|
+$13.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.46% |
| 2 | Miscellaneous | 14.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Labcorp
LH
$25.9B
| $49.4M | 14.69% |
225,902
+60,779
| +37% | +$13.4M |
2023 Q2
3 quarters
|
|
2
PUT
Insmed
INSM
$21.3B
| $37M | 11.01% |
1,362,700
+501,000
| +58% | +$14M |
2023 Q4
1 quarter
|
|
|
3
Cigna
CI
$75.3B
| $27.6M | 8.23% |
76,086
-40,467
| -35% | -$13.3M |
2020 Q3
14 quarters
|
|
4
Globus Medical
GMED
$10.1B
| $21.1M | 6.28% |
393,420
-138,669
| -26% | -$7.46M |
2023 Q1
4 quarters
|
|
|
5
Madrigal Pharmaceuticals
MDGL
$10.6B
| $13.6M | 4.06% |
+51,000
| New | +$12M |
2024 Q1
0 quarters
|
|
6
GSK
GSK
$95B
| $11.3M | 3.36% |
263,445
-307,946
| -54% | -$12.7M |
2023 Q2
3 quarters
|
|
7
Zimmer Biomet
ZBH
$17.4B
| $9.79M | 2.92% |
74,179
+1,879
| +3% | +$235K |
2023 Q3
2 quarters
|
|
|
8
Medtronic
MDT
$118B
| $9.15M | 2.72% |
+105,000
| New | +$8.96M |
2024 Q1
0 quarters
|
|
|
9
Organon & Co
OGN
$3.62B
| $9.01M | 2.68% |
+479,023
| New | +$8.22M |
2024 Q1
0 quarters
|
|
|
10
Tyra Biosciences
TYRA
$1.28B
| $8.79M | 2.62% |
+535,741
| New | +$8.79M |
2024 Q1
0 quarters
|
|
11
PUT
Ironwood Pharmaceuticals
IRWD
$595M
| $8.46M | 2.52% |
970,800
+807,400
| +494% | +$9.8M |
2023 Q4
1 quarter
|
|
12
Embecta
EMBC
$349M
| $7.77M | 2.31% |
585,418
-150,590
| -20% | -$2.33M |
2023 Q3
2 quarters
|
|
13
Teleflex
TFX
$5.24B
| $7.66M | 2.28% |
33,878
-2,649
| -7% | -$629K |
2023 Q3
2 quarters
|
|
14
Arcutis Biotherapeutics
ARQT
$3.36B
| $6.3M | 1.88% |
635,969
| – | – |
2023 Q2
3 quarters
|
|
15
BridgeBio Pharma
BBIO
$12.5B
| $6.28M | 1.87% |
203,174
+71,421
| +54% | +$2.43M |
2023 Q3
2 quarters
|
|
16
Humacyte
HUMA
$95.8M
| $6.22M | 1.85% |
+2,000,000
| New | +$6.73M |
2024 Q1
0 quarters
|
|
17
ANI Pharmaceuticals
ANIP
$1.64B
| $6.04M | 1.8% |
+87,354
| New | +$5.27M |
2024 Q1
0 quarters
|
|
18
DELISTED
Astria Therapeutics
ATXS
| $5.77M | 1.72% |
+410,267
| New | +$5.11M |
2024 Q1
0 quarters
|
|
19
ARS Pharmaceuticals
SPRY
$401M
| $5.48M | 1.63% |
536,163
-569,748
| -52% | -$4.25M |
2023 Q2
3 quarters
|
|
20
Healthcare Services Group
HCSG
$1.43B
| $5.26M | 1.57% |
421,317
-388,990
| -48% | -$4.31M |
2023 Q3
2 quarters
|
|
21
DELISTED
Apogee Therapeutics
APGE
| $5.18M | 1.54% |
+78,000
| New | +$3.41M |
2024 Q1
0 quarters
|
|
22
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $5.18M | 1.54% |
243,035
-3,001
| -1% | -$35.9K |
2020 Q4
13 quarters
|
|
23
Erasca
ERAS
$5.17B
| $5M | 1.49% |
+2,427,184
| New | +$4.85M |
2024 Q1
0 quarters
|
|
24
X4 Pharmaceuticals
XFOR
$247M
| $4.99M | 1.49% |
119,614
| – | – |
2023 Q2
3 quarters
|
|
25
Nuvation Bio
NUVB
$1.68B
| $4.86M | 1.45% |
+1,336,231
| New | +$2.57M |
2024 Q1
0 quarters
|
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q1 2024 Portfolio in Review
As of Q1 2024, Sio Capital Management held 65 positions worth $336M, down 24% from $439M the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Sio Capital Management withdrew a net $131M in Q1 2024, closing 14 positions and reducing 11 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $85.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 88% a quarter earlier, followed by Miscellaneous.
Against the trend, Sio Capital Management opened a new position in Madrigal Pharmaceuticals worth $13.6M.
- Sio Capital Management's largest Q1 2024 buy was Madrigal Pharmaceuticals: 51,000 shares worth $13.6M.
- Sio Capital Management added most to Labcorp in Q1 2024, an estimated $13.4M increase.
- Sio Capital Management's biggest Q1 2024 reduction was Cigna, cutting an estimated $13.3M.
- Sio Capital Management fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $85.3M.
- Sio Capital Management's ten largest holdings make up 59% of its $336M portfolio in Q1 2024.
- Sio Capital Management opened 22 new positions and closed 14 in Q1 2024.
- Sio Capital Management's portfolio value fell 24% quarter-over-quarter to $336M.
Based on Sio Capital Management's 13F filing for Q1 2024, filed 15 May 2024.